I'm not arguing that tissue concentration of a drug over an extended period in the small intestine is the primary and sole factor of GI drug efficiency nor the mechanism of action. However, Theravance Biopharma TD1473 candidate showed a quite noticeable difference in tissue concentration vs Xeijanx (tofactinib).

Why would this data comparison be filed in an SEC document - meaningless?

I'll leave it at that.